Search Results
Your search for ,wAS matches 27554 pages
Showing 18301 - 18350Steven K. Libutti, MD, FACS, Named Director of Rutgers Cancer Institute of New Jersey
Steven K. Libutti, MD, FACS, has been named the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University. When he takes on his new roles in early 2017, Dr. Libutti will be the third ...
Peer-Reviewed Indian Journal of Surgical Oncology Meets Challenges, Succeeds in Developing Country
Launching a new cancer journal is a risky and arduous endeavor, especially for a specialty publication in resource-challenged countries in the developing world. To succeed, a specialty journal must publish articles from established clinical researchers that quickly garner funding and captivate its...
Maura Gillison, MD, PhD, Elected to National Academy of Medicine
Maura Gillison, MD, PhD, a physician-researcher who has made significant contributions to the fields of cancer biology, therapy, and epidemiology, was elected a member of the National Academy of Medicine during the Academy’s annual meeting. Dr. Gillison is the Jeg Coughlin Chair in Cancer...
Precautions in Cancer Rehabilitation Services: Imperative or Impediment in Patient Care?
GUEST EDITOR Physiatry in Oncology explores the benefits of cancer rehabilitation in oncology practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. The column is guest edited by Sean Smith, ...
Roy S. Herbst, MD, PhD, Receives 2016 Paul A. Bunn Jr. Scientific Award
Roy S. Herbst, MD, PhD, of Yale University, New Haven, Connecticut, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a distinguished award at the 17th World Conference on Lung Cancer in Vienna, Austria. Dr. Herbst accepted the Paul A. Bunn Jr. Scientific...
AAAS Names Winship’s Dong Moon Shin, MD, as a 2016 Fellow
Dong Moon Shin, MD, the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research at Winship Cancer Institute of Emory University, has been named a Fellow of the American Association for the Advancement of Science (AAAS). Dr. Shin is Professor of Hematology and Medical Oncology,...
Mylin A. Torres, MD, to Hold Glenn Family Chair in Breast Cancer Research at Winship Cancer Institute
Mylin A. Torres, MD, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University (Winship), was selected to hold the Louisa and Rand Glenn Family Chair in Breast Cancer Research. The endowed position was created by the Wilbur and Hilda Glenn Family Foundation to...
William Sellers, MD, Appointed to Faculty at Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
William Sellers, MD, a widely respected cancer researcher with extensive experience in cancer genomics and therapeutic discovery, is returning to the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School (HMS) as a...
Friends of Cancer Research Rethinks Traditional Clinical Trials
Ellen V. Sigal, PhD, Chair and Founder of Friends of Cancer Research (Friends) began the annual meeting with a conversation with Douglas R. Lowy, MD, National Cancer Institute (NCI) Acting Director, and Robert M. Califf, MD, U.S. Food and Drug Administration (FDA) Commissioner. “Cancer research is ...
ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology
ASCO recently released its Criteria for High-Quality Clinical Pathways in Oncology, a set of 15 interrelated criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, utility, and...
UNC Lineberger’s Michael R. Kosorok, PhD, Elected AAAS Fellow
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center member Michael R. Kosorok, PhD, has been named a fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the journal Science. Dr. Kosorok, who ...
NCCN Launches Campaign to Eradicate Fatal Vincristine Errors
It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur. Now the National Comprehensive Cancer Network®...
Conquer Cancer Foundation Researcher Spotlight: Dr. Priscilla Brastianos
Priscilla Brastianos, MDDirector, Central Nervous System Metastasis ProgramMassachusetts General Hospital Cancer Center, Harvard Medical School, BostonMetastatic brain cancer People are inspired to pursue careers in cancer research for any number of reasons: They might like the challenging nature...
Sodium Thiosulfate Seems to Protect Against Cisplatin-Related Hearing Loss in Children With Cancer
The antioxidant sodium thiosulfate provided protection against cisplatin-related hearing loss in children with cancer, according to a phase III trial reported by Freyer et al in The Lancet Oncology. The open-label trial included 104 assessable patients (aged 1 to 18 years) from 38 Children’s ...
A Decade of Impact: Conquer Cancer Foundation/Kidney Cancer Association Young Investigator Awards
The Kidney Cancer Association has supported 12 kidney cancer research projects through the Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) program over the past decade. Early seed funding from the Kidney Cancer Association is advancing research, improving the lives of ...
Christine Laronga, MD, FACS, Elected President of the Association of Women Surgeons
Christine Laronga, MD, FACS, a surgical oncologist specializing in breast cancer at Moffitt Cancer Center, has been named President of the Association of Women Surgeons. The international organization has more than 1,800 members and represents 21 countries. “I am thrilled to be in this new...
ASH Launches Digital, Open-Access Journal Blood Advances at 2016 Annual Meeting
Blood has covered experimental and clinical hematologic research as the flagship journal of the American Society of Hematology (ASH). Launched officially on November 29, 2016, the open-access online journal Blood Advances will fill a niche that complements and expands on topics covered in Blood...
What’s New in Antiemesis Therapy
The optimal use of new antiemetics was the subject of a presentation at the 14th Annual School of Breast Oncology, Emory University, Atlanta, by Frankie Ann Holmes, MD, Associate Director of Breast Oncology Research at Texas Oncology, Houston. “The science of nausea and vomiting is so compelling,...
Treatment of Early HER2-Positive Breast Cancer: One Size Does Not Fit All
Despite the routine use of HER2 blockade in early HER2-positive breast cancer, clinicians can always benefit from a refresher on key treatment considerations. Clinical pearls and controversial issues were the topic of a presentation at the 14th Annual School of Breast Oncology at Emory University, ...
The FDA Ensures Quality and Safety of Generic Drugs in the United States
The U.S. Food and Drug Administration’s (FDA) generic drug program has substantially increased the availability of affordable, high-quality drugs in the United States. It is arguably the only really effective health-care cost–containment program. The more than 10,000 generic drugs currently...
David Tuveson, MD, PhD, Named Director of the Cold Spring Harbor Laboratory Cancer Center
David Tuveson, MD, PhD, will succeed Bruce Stillman, AO, FAA, FRS, as Director of the Cold Spring Harbor Laboratory Cancer Center. Dr. Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, the Head of the Lustgarten Foundation Pancreatic Cancer Research...
Fergus J. Couch, PhD, and Max S. Wicha, MD, Recognized for Significant Contributions to Breast Cancer Research at 2016 SABCS
The American Association for Cancer Research (AACR) honored two renowned researchers for their work in breast cancer at the 2016 San Antonio Breast Cancer Symposium (SABCS), held December 6–10 in San Antonio, Texas. Fergus J. Couch, PhD, of the Mayo Clinic, will receive the 9th Annual AACR...
Concerns About Safety of Generic Oncology Drugs Made in Developing Countries
In an article in The Lancet Oncology, Y. Tony Yang, ScD, of George Mason University, Charles L. Bennett, MD, PhD, MPP, of the University of South Carolina and colleagues from the United States, Europe, and Japan examined clinical, policy, safety, and regulatory considerations for generic oncology...
SABCS 2016: Extended Letrozole Therapy Showed Limited Benefit in Postmenopausal Women With Early-Stage, Hormone Receptor–Positive Breast Cancer
Five additional years of hormone therapy with letrozole following an initial 5 years of aromatase inhibitor-based adjuvant hormone therapy did not demonstrate a statistical improvement in disease-free survival or overall survival in postmenopausal women with early-stage hormone...
SABCS 2016: Adding Everolimus to Fulvestrant Improved Outcomes for Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
Progression-free survival was more than doubled for patients with metastatic hormone receptor–positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment with the endocrine therapeutic fulvestrant (Faslodex), according to data...
Elizabeth M. Swisher, MD, Finds Juggling Research Projects and Clinical Care Improves Both
Elizabeth M. Swisher, MD, Medical Director of the Breast and Ovarian Cancer Prevention Program at the Seattle Cancer Care Alliance, enjoys developing long-term patient relationships and helping patients who are confronted with cancer and terminal issues. She is particularly interested in the...
Randi Kaplan, LMSW, Named Schwartz Center’s 2016 National Compassionate Caregiver of the Year
The Schwartz Center for Compassionate Healthcare, a national leader in providing compassionate care to patients and caregivers, has named Randi Kaplan, LMSW, Director of the Arthur D. Emil Caregiver Support Center at Montefiore, the National Compassionate Caregiver of the Year. The prestigious...
Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...
Daratumumab in Previously Treated Multiple Myeloma
On November 21, 2016, daratumumab (Darzalex) was approved for use in combination with lenalidomide (Revlimid) and dexamethasone or with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.1,2 The drug was initially ...
No Progression-Free Survival Difference With Temozolomide vs Radiotherapy in High-Risk Low-Grade Glioma
In a phase III intergroup trial reported in The Lancet Oncology, Brigitta G. Baumert, MD, of the European Organisation for Research and Treatment of Cancer (EORTC), Brussels, and colleagues found no progression-free survival difference between temozolomide chemotherapy and radiotherapy alone in...
Johns Hopkins Kimmel Cancer Center Expands Cancer Care and Research Facility at Sibley Memorial Hospital in Washington, DC
Cancer experts from the Johns Hopkins Kimmel Cancer Center are now embedded in a newly expanded facility within Johns Hopkins Medicine–owned Sibley Memorial Hospital in northwest Washington, DC. Sibley recently opened the 30,000-square-foot medical oncology facility—part of its new...
New Treatments for Lung Cancer in 2016
With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that target anaplastic lymphoma kinase (ALK) rearrangements, 2016 has been an extraordinary year for lung...
Disparities of Care: Navigation System Helps Connect Underserved Populations to Cancer Services
Although we’ve seen substantial progress in cancer treatment, screening, diagnosis, and prevention over the past decades, certain underserved populations have not reaped the benefits of many of these advances. Turning research into actionable programs in this area was highlighted by a presentation ...
NCI Study Affirms There Is No Safe Level of Smoking
People who consistently smoked an average of less than 1 cigarette per day over their lifetime had a 64% higher risk of earlier death than never-smokers, and those who smoked between 1 and 10 cigarettes a day had an 87% higher risk of earlier death than never-smokers, according to a new study from...
Bad Year for Brain Tumors, but Still Reasons for Hope
Checkpoint inhibitors and targeted therapies are reshaping the landscape of cancer care across multiple tumor sites, but treatments for brain tumors remain decidedly unchanged. The standard of care for high-grade gliomas in the front-line setting—a combination of surgery and chemoradiation—is the...
Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
On November 10, 2016, nivolumab (Opdivo) was approved for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy.1,2 Supporting Efficacy Data Approval was based on the finding of an overall survival advantage...
Mutanome-Directed Immunotherapy: Finding the Best Treatment Match
Oncologists may be accustomed to looking for commonalities in patients, but highly personalized therapies are now being developed based on mutational analysis of tumors. According to data presented at the Cedars-Sinai annual symposium on New Therapeutics in Oncology: The Road to Personalized...
Liquid Biopsies Identify Molecular Alterations Driving Drug Resistance in Nearly 80% of Patients With Gastrointestinal Cancers
Liquid biopsy technologies are increasingly being used to detect genetic mutations in tumors, giving clinicians the opportunity to see in real time how a patient’s cancer may or may not be responding to treatment. In a study presented recently at the 28th EORTC-NCI-AACR Symposium on Molecular...
Noteworthy Antitumor Activity Seen in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes encode receptor tyrosine kinases, and when they are mutated, cell signaling malfunctions, leading to...
Genetic Link May Explain Outcomes Differences in Multiple Myeloma in African Americans
African Americans are more than twice as likely as their white counterparts to be diagnosed with multiple myeloma, and twice as likely to die from this form of cancer. Research presented at the 9th American Association for Cancer Research (AACR) Conference on the Science of Cancer Health...
Novel Immunotherapy Combinations May Be the Future of Melanoma Treatment
The future treatment of melanoma may rely on combinations of immunotherapy agents beyond the current checkpoint inhibitors, and they are entering clinical trials, according to Jeffrey Weber, MD, PhD, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone...
FDA Approves Daratumumab in Combination Therapy for Patients With Multiple Myeloma Receiving at Least One Prior Treatment
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior...
MD Anderson Cancer Center Marks 75 Years of Research to End Cancer
In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of...
Experts Consider the New Immunotherapy Paradigm in Advanced Lung Cancer
One immune checkpoint inhibitor has now moved to the front of the line for treating advanced non–small cell lung cancer (NSCLC). Based on pivotal studies presented at the 2016 European Society for Medical Oncology (ESMO) Congress, pembrolizumab (Keytruda) became a first-line option, and it is...
‘Clinically Useful’ Findings for Brentuximab Vedotin in CTCL, Rituximab Maintenance in MCL
Positive studies about brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma1 and rituximab (Rituxan) maintenance therapy in mantle cell lymphoma (MCL)2 were reported at the 2016 Annual Meeting of the American Society for Hematology (ASH). “These abstracts each focus on approved agents and...
Medicare Access and CHIP Reauthorization Act: The Final Rule
It is gratifying to see the Centers for Medicare & Medicaid Services (CMS) does listen to public comments regarding new proposals. Since CMS opened the comment period for its Quality Payment Program, which repeals the Sustainable Growth Rate Formula and was proposed to implement the Medicare...
Successful Retreatment With Cisplatin-Based Therapy Reported in Men Relapsing After Adjuvant Carboplatin for Stage I Seminoma
In an analysis reported in the Journal of Clinical Oncology, Fischer et al found that men with clinical stage I seminoma who relapsed after adjuvant carboplatin could be successfully re-treated with cisplatin-based chemotherapy. Study Details The analysis included data from 185 patients who...
No Significant Benefit of Perindopril or Bisoprolol in Reducing Trastuzumab-Associated Cardiac Remodeling in HER2-Positive Breast Cancer
Use of the angiotensin-converting enzyme inhibitor perindopril or the beta-blocker bisoprolol did not reduce the risk of trastuzumab (Herceptin)-related cardiac remodeling in women with HER2-positive early breast cancer, according to a Canadian trial reported by Pituskin et al in the Journal of...
Equivalent Response Rates With Trastuzumab or Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer
In part 1 of a phase III equivalence trial reported in JAMA, Rugo et al found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar in combination with a taxane produced similar overall response rates in patients with previously untreated metastatic HER2-positive breast...
ASH 2016: Children With Down Syndrome and ALL Fare as Well as Other Children Treated on ALL Consortium Protocols
Despite an elevated risk of toxicity from chemotherapy, children with Down syndrome and acute lymphoblastic leukemia (ALL) did not experience higher rates of relapse or treatment-related mortality compared with other children treated on Dana-Farber Cancer Institute ALL Consortium Protocols,...
